Nevro Corp (NVRO) Stock Price, Quote & News

suntanner20 Jun. 17 at 8:03 PM

$MLSS all about the contacts. the best in biz is based on contacts $NVRO is where new BoD was from

0 · Reply

suntanner20 Jun. 16 at 3:09 PM

$MLSS someone took size .8950-.91 we MUST be close $NVRO executives ?

0 · Reply

suntanner20 Jun. 13 at 1:17 PM

$MLSS Table Is Set: Everyone needs to eat. In fact, everyone loves to eat a great big home cooked meal, but not everyone loves to do what it takes to deliver that arduous task. That brings us to what potentially could be one of the most savoring investments in the micro cap space that just might be all set up for making that brokerage account adequately full when it’s all said and done. The investment is Milestone Scientific (MLSS .90) a medical device company that specializes in a device that delivers a one of a kind, AI pressurized syringe for the epidural market today, but the platform could bolster many new applications in the not too distant future. The reality is the company has done a lot of the heavy lifting to get themselves to invite as many new shareholders to the table that we believe is set to eat. Shanth Thiyagalingam Brought into MLSS 3 weeks ago COULD be the Chef needed to find all the ingredients $NVRO $ABT

0 · Reply

suntanner20 Jun. 11 at 5:04 PM

$MLSS someone collecting blocks of stock CANNOT BE LONG!!!!! $NVRO

1 · Reply

suntanner20 Jun. 11 at 1:44 PM

$MLSS This is NOT 1.00 stock much longer. I noticed new BoD was at $NVRO 3-50 then 130 cmon 5.00

0 · Reply

BioTechHealthX Jun. 8 at 6:31 PM

$NVRO With groundbreaking tech, strong IP, & rising international demand, Nevro might be undervalued even with the Globus Medical's acquisition. https://biotechhealthx.com/biotech-news/nevro-nvro-could-surge-beyond-its-buyout-offer-in-2025/

0 · Reply

Love_To_Learn Apr. 3 at 1:13 PM

$NVRO coding the halt now

0 · Reply

NVDAMillionaire Mar. 21 at 9:46 AM

$NVRO Digging Nevro's AI-powered pain management tech. HFX AdaptivAI looks promising. Might initiate a small position to play the chronic pain innovation angle. Watching closely for clinical expansion potential. noteworthy article: https://beyondspx.com/article/nevro-corp-nvro-delivering-innovative-solutions-for-chronic-pain-management

1 · Reply

Estimize Mar. 5 at 11:00 AM

$NVRO reported -1.41 EPS and 105.55 revenue for Q4. http://www.estimize.com/intro/nvro?chart=historical&metric_name=eps&utm_content=NVRO&ut

0 · Reply

Estimize Mar. 4 at 4:00 PM

$NVRO reports after the close, Estimize Consensus +0.06 EPS and +1.79M Revs compared to WS http://www.estimize.com/nvro/fq4-2024?utm_conten

0 · Reply

Nevro Corp. Investigated by Federman & Sherwood for Data Breach

Mar 21, 2025, 11:30 AM EDT - 1 year ago

NEVRO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nevro Corp. - NVRO

GMED

Mar 4, 2025, 4:15 PM EST - 1 year ago

Nevro Reports Fourth-Quarter and Full-Year 2024 Financial Results

GMED

Jan 21, 2025, 4:30 PM EST - 1 year ago

Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08

Jan 13, 2025, 8:30 AM EST - 1 year ago

Nevro Announces Preliminary Fourth-Quarter and Full-Year 2024 Revenue Results

Dec 2, 2024, 2:29 PM EST - 1 year ago

Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos

GKOS ISRG SYK

Nov 18, 2024, 8:30 AM EST - 1 year ago

New Study Demonstrates Multiple Advantages of Nevro1™, the Novel SI Joint Fusion System by Nevro, in Comparison to Posterolateral and Lateral Approaches

Nov 12, 2024, 7:00 AM EST - 1 year ago

Nevro's HFX iQ™ Spinal Cord Stimulation with AI Technology Receives CE Mark Certification in Europe, Increasing Product Expansion Globally

Nov 11, 2024, 9:11 PM EST - 1 year ago

Nevro Corp. (NVRO) Q3 2024 Earnings Call Transcript

Nov 11, 2024, 4:05 PM EST - 1 year ago

Nevro Reports Third-Quarter 2024 Financial Results

Oct 29, 2024, 4:30 PM EDT - 1 year ago

New Data Demonstrates Long-Term Improvements in Pain Intensity with Nevro's High-Frequency Spinal Cord Stimulation Therapy

Oct 10, 2024, 4:45 PM EDT - 1 year ago

Nevro to Report Third-Quarter 2024 Financial Results and Host Earnings Conference Call on November 11, 2024

Sep 24, 2024, 8:00 AM EDT - 1 year ago

Nevro Announces the Launch of HFX AdaptivAI™, the Only AI-Driven Technology in Spinal Cord Stimulation

Aug 28, 2024, 4:15 PM EDT - 1 year ago

Nevro to Present at Wells Fargo 2024 Healthcare Conference

Aug 9, 2024, 3:47 PM EDT - 1 year ago

Nevro: Not Having My Back

Aug 7, 2024, 5:54 AM EDT - 1 year ago

Nevro Corp. (NVRO) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 4:05 PM EDT - 1 year ago

Nevro Reports Second-Quarter 2024 Financial Results

Jul 9, 2024, 4:15 PM EDT - 1 year ago

Nevro to Report Second-Quarter 2024 Financial Results and Host Earnings Conference Call on August 6, 2024

Jun 11, 2024, 4:15 PM EDT - 1 year ago

Nevro to Present at Truist Securities MedTech Conference

May 9, 2024, 4:05 PM EDT - 1 year ago

Nevro to Present at BofA Securities 2024 Healthcare Conference

May 8, 2024, 2:01 AM EDT - 2 years ago

Nevro Corp. (NVRO) Q1 2024 Earnings Call Transcript

May 7, 2024, 4:05 PM EDT - 2 years ago

Nevro Reports First-Quarter 2024 Financial Results

Apr 17, 2024, 8:30 AM EDT - 2 years ago

Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024

Feb 28, 2024, 4:10 PM EST - 2 years ago

Nevro Receives FDA 510(k) Clearance to Use SI Fixation System Without Need to Include Lateral Screw

Feb 21, 2024, 11:02 PM EST - 2 years ago

Nevro Corp. (NVRO) Q4 2023 Earnings Call Transcript

Feb 21, 2024, 4:06 PM EST - 2 years ago

Nevro Enters Into Cooperation Agreement With Engaged Capital

Feb 21, 2024, 4:05 PM EST - 2 years ago

Nevro Reports Fourth-Quarter and Full-Year 2023 Financial Results

$Nevro Announces Consensus Statement Supporting High-Frequency (10 kHz) Spinal Cord Stimulation Therapy for Refractory Painful Diabetic Neuropathy$

Feb 1, 2024, 4:30 PM EST - 2 years ago

Nevro Announces Consensus Statement Supporting High-Frequency (10 kHz) Spinal Cord Stimulation Therapy for Refractory Painful Diabetic Neuropathy

Jan 29, 2024, 4:30 PM EST - 2 years ago

Nevro to Report Fourth-Quarter and Full-Year 2023 Financial Results and Host Conference Call on February 21, 2024

Jan 18, 2024, 4:15 PM EST - 2 years ago

Nevro Announces Positive Coverage Update from Carelon Healthcare for the Treatment of Painful Diabetic Neuropathy

Jan 17, 2024, 4:15 PM EST - 2 years ago

Nevro to Highlight 25 Scientific Abstracts at 2024 North American Neuromodulation Society (NANS) Annual Meeting

Jan 9, 2024, 8:50 AM EST - 2 years ago

Nevro laying off 63 employees; revenue to beat analyst estimates

Jan 9, 2024, 8:30 AM EST - 2 years ago

Nevro Announces Preliminary Fourth-Quarter and Full-Year 2023 Revenue Results

Jan 4, 2024, 4:15 PM EST - 2 years ago

Nevro to Present at 42nd Annual J.P. Morgan Healthcare Conference

Nov 30, 2023, 5:19 PM EST - 2 years ago

Nevro Announces Acquisition of Vyrsa™ Technologies

$Nevro Delivers Long-Term Relief with High-Frequency Spinal Cord Stimulation: 24-Month Data Demonstrates Profound Improvements for Non-Surgical Refractory Back Pain$

Nov 20, 2023, 7:00 AM EST - 2 years ago

Nevro Delivers Long-Term Relief with High-Frequency Spinal Cord Stimulation: 24-Month Data Demonstrates Profound Improvements for Non-Surgical Refractory Back Pain

Nov 1, 2023, 4:01 PM EDT - 2 years ago

Nevro Reports Third Quarter 2023 Financial Results, Provides Fourth Quarter Guidance and Updates Full-Year 2023 Guidance

Oct 4, 2023, 7:00 AM EDT - 2 years ago

Nevro to Report Third Quarter 2023 Financial Results

Sep 18, 2023, 7:00 AM EDT - 2 years ago

New Data Demonstrate the Health Economic Benefits of Nevro's High-Frequency Spinal Cord Stimulation Therapy

Sep 1, 2023, 3:54 PM EDT - 2 years ago

Nevro: Economic Realities Too Deep To Ignore, Downgrade To Hold

Aug 23, 2023, 7:00 AM EDT - 2 years ago

Nevro Announces Participation in Upcoming Investor Conferences

suntanner20 Jun. 17 at 8:03 PM

$MLSS all about the contacts. the best in biz is based on contacts $NVRO is where new BoD was from

0 · Reply

suntanner20 Jun. 16 at 3:09 PM

$MLSS someone took size .8950-.91 we MUST be close $NVRO executives ?

0 · Reply

suntanner20 Jun. 13 at 1:17 PM

0 · Reply

suntanner20 Jun. 11 at 5:04 PM

$MLSS someone collecting blocks of stock CANNOT BE LONG!!!!! $NVRO

1 · Reply

suntanner20 Jun. 11 at 1:44 PM

$MLSS This is NOT 1.00 stock much longer. I noticed new BoD was at $NVRO 3-50 then 130 cmon 5.00

0 · Reply

BioTechHealthX Jun. 8 at 6:31 PM

0 · Reply

Love_To_Learn Apr. 3 at 1:13 PM

$NVRO coding the halt now

0 · Reply

NVDAMillionaire Mar. 21 at 9:46 AM

1 · Reply

Estimize Mar. 5 at 11:00 AM

$NVRO reported -1.41 EPS and 105.55 revenue for Q4. http://www.estimize.com/intro/nvro?chart=historical&metric_name=eps&utm_content=NVRO&ut

0 · Reply

Estimize Mar. 4 at 4:00 PM

$NVRO reports after the close, Estimize Consensus +0.06 EPS and +1.79M Revs compared to WS http://www.estimize.com/nvro/fq4-2024?utm_conten

0 · Reply

DonCorleone77 Feb. 8 at 5:34 PM

$NVRO Nevro upgraded to Hold from Underperform at Jefferies Jefferies upgraded Nevro to Hold from Underperform with a price target of $5.85, up from $4.50, after the company entered into a definitive agreement for Globus Medical to acquire all its shares for $5.85 per share.

0 · Reply

PenkeInvesting Feb. 6 at 11:31 PM

I found you an Overbought RSI (Relative Strength Index) on the daily chart of Nevro Corp. Is that bullish or bearish? $NVRO #Nevro #RsiOverbought #NYSE

0 · Reply

ajmrtxl Feb. 6 at 6:48 PM

$NVRO real-time squeeze play

1 · Reply

Muddymac Feb. 6 at 3:05 PM

$NVRO https://stocks.apple.com/A1x9npE6ySxONebBwJHq_7Q Sad ending. $250M valuation is embarrassing.

1 · Reply

Muddymac Jan. 31 at 3:55 AM

$NVRO Stryker announced it is selling off its spinal implant business. They would have been the most logical of the big strategic companies that have a spinal business to acquire NVRO. Makes you wonder if the stim market is stagnating or going backwards.

2 · Reply

BPharmCatalyst Jan. 13 at 9:38 PM

$PHIO shares closed up 291% at $6.6 following results from the second dose cohort of its ongoing Phase 1b trial evaluating intratumoral PH-762 in various skin cancers. See More Biotech Updates👇 https://www.biopharmcatalyst.com/news/2025/phio-phio-phase-1b-data-salarius-slrx-decoy-merger $PHIO $SLRX $NAYA $SAGE $ITCI $TRAW $MRNA $NVRO

0 · Reply

Market Cap	224.09M
Revenue (ttm)	408.52M
Net Income (ttm)	-113.44M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-27.77%
Debt to Equity Ratio	0.98

Volume	753,600
Avg Vol	1,348,482
Day's Range	N/A - N/A
Shares Out	38.37M
Stochastic %K	78%
Beta	0.82
Analysts	Hold
Price Target	$5.44